Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anterix Inc.ATEX · Entity 4597 | Chief Financial Officer | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anterix Inc.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,604 |
Ending reported balance
After 2026-10-09 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-10-09 · Sale · Disposed 3,254 · Balance 13,104 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4. Row 2 · 2026-10-09 · Sale · Disposed 400 · Balance 12,704 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2026. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.45 to $82.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4. Row 3 · 2026-10-09 · Sale · Disposed 100 · Balance 12,604 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2026. Row 4 · 2026-10-09 · Exercise / conversion · Acquired 1,227 · Balance 13,831 Row 5 · 2026-10-09 · Sale · Disposed 1,017 · Balance 12,814 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4. Row 6 · 2026-10-09 · Sale · Disposed 210 · Balance 12,604 F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2026. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.765 to $82.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.00 · Expires 2035-04-03 | Direct | 1,227 |
Reported balance
After 2026-10-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-09 · Exercise / conversion · Disposed 1,227 · Balance 1,227 F5: The option shares vest and become exercisable in three equal annual installments beginning on October 4, 2025 |
Filing footnotes · ownership attribution and instrument terms
F1: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.45 to $82.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.765 to $82.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4.
F5: The option shares vest and become exercisable in three equal annual installments beginning on October 4, 2025
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 11:57 UTC | Anterix Inc. ATEX · Entity 4597 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,227 | $0.00 Strike: $40.00 | $0.00 |
DisclosureSEC source: 0002090789-26-000016 · wk-form4_1791892643.xml · derivative · entry 7 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,227 Underlying: Common Stock · 1,227 shares Expires 2035-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option shares vest and become exercisable in three equal annual installments beginning on October 4, 2025 Read SEC document |
| October 09, 2026 Filed Oct 13, 2026 11:57 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 210 | $81.90 | $17,198.85 |
DisclosureSEC source: 0002090789-26-000016 · wk-form4_1791892643.xml · nonDerivative · entry 6 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,604 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2026. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.765 to $82.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 09, 2026 Filed Oct 13, 2026 11:57 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 1,017 | $80.22 | $81,588.52 |
DisclosureSEC source: 0002090789-26-000016 · wk-form4_1791892643.xml · nonDerivative · entry 5 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,814 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 09, 2026 Filed Oct 13, 2026 11:57 UTC | Anterix Inc. ATEX · Entity 4597 | Exercise / conversionCommon Stock | 1,227 | $40.00 | $49,080.00 |
DisclosureSEC source: 0002090789-26-000016 · wk-form4_1791892643.xml · nonDerivative · entry 4 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 09, 2026 Filed Oct 13, 2026 11:57 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 100 | $82.50 | $8,250.00 |
DisclosureSEC source: 0002090789-26-000016 · wk-form4_1791892643.xml · nonDerivative · entry 3 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,604 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2026. Read SEC document |
| October 09, 2026 Filed Oct 13, 2026 11:57 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 400 | $81.80 | $32,720.00 |
DisclosureSEC source: 0002090789-26-000016 · wk-form4_1791892643.xml · nonDerivative · entry 2 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,704 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2026. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.45 to $82.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 09, 2026 Filed Oct 13, 2026 11:57 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 3,254 | $80.16 | $260,849.43 |
DisclosureSEC source: 0002090789-26-000016 · wk-form4_1791892643.xml · nonDerivative · entry 1 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,104 F1 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 21:22 UTC | Anterix Inc. ATEX · Entity 4597 | Tax withholdingCommon Stock | 473 | $84.33 | $39,888.09 |
DisclosureSEC source: 0002090789-26-000013 · wk-form4_1791321720.xml · nonDerivative · entry 1 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,358 F1 · shares: The shares were withheld by the Issuer to satisfy withholding obligations in connection with the partial vesting and settlement of restricted stock units. Read SEC document |
| July 13, 2026 Filed Jul 14, 2026 20:10 UTC | Anterix Inc. ATEX · Entity 4597 | Tax withholdingCommon Stock | 231 | $100.96 | $23,321.76 |
DisclosureSEC source: 0002090789-26-000009 · wk-form4_1784059848.xml · nonDerivative · entry 1 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,156 F1 · shares: The shares were withheld by the Issuer to satisfy withholding obligations in connection with the partial vesting and settlement of restricted stock units. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:40 UTC | Anterix Inc. ATEX · Entity 4597 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,226 | $0.00 Strike: $40.00 | $0.00 |
DisclosureSEC source: 0002090789-26-000007 · wk-form4_1781815233.xml · derivative · entry 3 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,454 Underlying: Common Stock · 1,226 shares Expires 2035-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option shares vest and become exercisable in three equal annual installments beginning on October 4, 2025. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:40 UTC | Anterix Inc. ATEX · Entity 4597 | SaleCommon Stock | 4,291 | $79.50 | $341,134.50 |
DisclosureSEC source: 0002090789-26-000007 · wk-form4_1781815233.xml · nonDerivative · entry 2 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,387 Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 20:40 UTC | Anterix Inc. ATEX · Entity 4597 | Exercise / conversionCommon Stock | 1,226 | $40.00 | $49,040.00 |
DisclosureSEC source: 0002090789-26-000007 · wk-form4_1781815233.xml · nonDerivative · entry 1 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:47 UTC | Anterix Inc. ATEX · Entity 4597 | GrantStock Option (Right to Buy) · Derivative | 17,453 | $0.00 Strike: $60.90 | $0.00 |
DisclosureSEC source: 0002090789-26-000005 · wk-form4_1779493668.xml · derivative · entry 2 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,453 Underlying: Common Stock · 17,453 shares Expires 2036-05-20 F2 · derivative.exercise_date: The option shares vest and become exercisable over three years, with 1/3 vesting on May 20, 2027, and 1/12 vesting quarterly thereafter on August 10, November 10, February 10, and May 20 of each year through May 20, 2029. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:47 UTC | Anterix Inc. ATEX · Entity 4597 | GrantCommon Stock | 3,694 | $0.00 | $0.00 |
DisclosureSEC source: 0002090789-26-000005 · wk-form4_1779493668.xml · nonDerivative · entry 1 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,452 F1 · shares: Represents the issuance of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer's Common Stock. The RSUs vest over three years, with 1/3 vesting on May 20, 2027, and 1/12 vesting quarterly thereafter on August 10, November 10, February 10, and May 20 of each year through May 20, 2029. Read SEC document |
| May 15, 2026 Filed May 19, 2026 13:29 UTC | Anterix Inc. ATEX · Entity 4597 | Tax withholdingCommon Stock | 271 | $56.62 | $15,344.02 |
DisclosureSEC source: 0002090789-26-000003 · wk-form4_1779197391.xml · nonDerivative · entry 1 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,758 F1 · shares: The shares were withheld by the Issuer to satisfy withholding obligations in connection with the partial vesting and settlement of restricted stock unit. Read SEC document |
| October 04, 2025 Filed Nov 5, 2025 00:15 UTC | Anterix Inc. ATEX · Entity 4597 | Tax withholdingCommon Stock | 404 | $22.55 | $9,110.20 |
DisclosureSEC source: 0002090789-25-000004 · wk-form4_1762301728.xml · nonDerivative · entry 2 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,029 F2 · shares: The shares were withheld by the Issuer to satisfy withholding obligations in connection with the partial vesting and settlement of restricted stock units. Read SEC document |
| September 29, 2025 Filed Nov 5, 2025 00:15 UTC | Anterix Inc. ATEX · Entity 4597 | GrantCommon Stock | 11,405 | $0.00 | $0.00 |
DisclosureSEC source: 0002090789-25-000004 · wk-form4_1762301728.xml · nonDerivative · entry 1 Marquez Elena · CIK 0002090789 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,433 F1 · shares: Represents the issuance of restricted stock units (the "RSUs"). 1/3 of the units vest on September 29, 2026, with the remaining RSUs vesting in 2 equal annual installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.